Recurrent seizure at 18 months · children with febrile seizures
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Recurrent seizure at 24 months · children with febrile seizures
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Recurrent seizure at 36 months · children with febrile seizures
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Recurrent seizure at 48 months · children with febrile seizures
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Recurrent seizure at 60 months or greater · children with febrile seizures
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Rate of decline of serum bilirubin (micromol/L/hr) · neonatal jaundice
1 finding from 1 review
Bilirubin‐induced brain dysfunction (defined as either the pathological finding of deep‐yellow staining of neurons and neuronal necrosis of the basal ganglia and brainstem nuclei or acute or chronic neurological deficit including athetoid cerebral... · neonatal jaundice
1 finding from 1 review
Treatment failure (need to restart phototherapy or exchange transfusion or both) · neonatal jaundice
1 finding from 1 review
Mortality (all cause) · neonatal jaundice
1 finding from 1 review
Global state: average score: long term (+ 26 weeks) Global Assessment Scale (GAS). Scale from: 0 to 100. · patients with schizophrenia
1 finding from 1 review
Mental state · patients with schizophrenia
1 finding from 1 review
Adverse effects: tardive dyskinesia: long term (+ 26 weeks) as defined in each study · patients with schizophrenia
INTERMITTENT (EARLY‐BASED) showed no clear difference in adverse effects: tardive dyskinesia: long term (+26 weeks) as… compared with MAINTENANCE THERAPY (low certainty).
1 finding from 1 review
Cost‐effectiveness · patients with schizophrenia
1 finding from 1 review
Leaving the study early/ loss to · patients with schizophrenia
INTERMITTENT (EARLY‐BASED) may leads to higher leaving the study early/loss to compared with MAINTENANCE THERAPY (low certainty).
1 finding from 1 review
Relapse · patients with schizophrenia
INTERMITTENT (EARLY‐BASED) may leads to higher relapse: long term (+ 26 weeks) as defined in each study compared with MAINTENANCE THERAPY (low certainty).
1 finding from 1 review
Hospital admissions · patients with schizophrenia
INTERMITTENT (EARLY‐BASED) probably leads to higher hospitalisation: long term (+ 26 weeks) as defined in each study compared with MAINTENANCE THERAPY (moderate certainty).
1 finding from 1 review
Fall in PTH · patients with bone disease in children with chronic kidney disease
Intermittent oral showed no clear difference in fall in PTH compared with daily oral calcitriol (moderate certainty).
2 findings from 1 review
Kidney function · patients with bone disease in children with chronic kidney disease
1 finding from 1 review
Adverse events ‐ Calcium > 11.5 mg/dL · patients with bone disease in children with chronic kidney disease
1 finding from 1 review
Adverse events ‐ Phosphorus level > 7.5 mg/dL · patients with bone disease in children with chronic kidney disease
1 finding from 1 review